Phase 3
N=7
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Juvenile Idiopathic Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT01667471 ↗Enrolled (actual)
7
Serious AEs
14.3%
Results posted
Oct 2015
Primary outcome: Primary: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events — 6; 0; 1; 1 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- tocilizumab [RoActemra/Actemra] (Drug)
- Age
- Pediatric, Adult · 9+ yrs
- Sex
- All
- Sponsor
- Hoffmann-La Roche
- Primary completion
- Aug 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events |
6; 0; 1; 1 | — |
| PRIMARY Number of AEs of Special Interest and Study Drug Related AEs |
22; 0; 2; 2 | — |
| SECONDARY Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit |
85.7; 100.0; 100.0; 100.0; 100.0; 100.0 | — |
| SECONDARY Percentage of Participants With Inactive Disease by Visit |
57.1; 42.9; 14.3; 42.9; 16.7; 33.3 | — |
| SECONDARY Percentage of Participants Achieving Clinical Remission (CR) at Each Visit |
0.0; 0.0; 0.0; 0.0; 0.0; 0.0 | — |
| SECONDARY Physicians Assessment of Global Activity (VAS) |
12.0; 2.3; 5.4; 1.0; 29.0; 5.0 | — |
| SECONDARY Parent or Participant's Assessment of Global Activity (VAS) |
10.1; 7.1; 16.4; 1.0; 22.5; 12.1 | — |
| SECONDARY Number of Joints With Active Arthritis |
0.9; 0.3; 1.0; 1.0; 1.5; 1.1 | — |
| SECONDARY Number of Joints With Lack of Motion |
1.4; 2.6; 2.4; 1.0; 5.5; 1.7 | — |
| SECONDARY Erythrocyte Sedimentation Rate |
4.9; 3.0; 2.9; 3.0; 8.6; 2.6 | — |
| SECONDARY CHAQ-DI Score |
0.0; 0.04; 0.14; 0.00; 0.19; 0.13 | — |
| SECONDARY Parent or Participant's Assessment of Pain (VAS) |
10.9; 7.0; 13.7; 1.0; 28.5; 10.6 | — |
| SECONDARY CRP Levels |
0.03; 0.05; 0.02; 0.03; 0.23; 0.05 | — |
Summary
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
Eligibility Criteria
Inclusion Criteria
- Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment
- Scheduled to receive first RoActemra/Actemra infusion in this study between 4 and 6 weeks after the last IV infusion in the core study
- Females of child-bearing potential and males with female partners of child-bearing potential must agree to use effective contraception as defined by protocol
Exclusion Criteria
- Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
- Treatment with any investigational agent since the last administration of study drug in the core study WA19977 or current participation in another clinical trial except WA19977
- Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
- Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
- Any significant concomitant disease or medical or surgical condition
- History of significant allergic or infusion reactions to prior biologic therapy
- Known current active acute, subacute, chronic or history of recurrent infection; patients suffering from ongoing active infections with Epstein Barr virus, herpes zoster or recurrent history of urinary tract infection can be included after the (acute) infection has been excluded or subsided
- Positive for latent tuberculosis (TB)
- Currently active asthma for which the patient has required the use of oral or parenteral corticosteroids for >/= 2 weeks within 6 months prior to entering the study
- Inadequate hepatic, renal or bone marrow function
Data sourced from ClinicalTrials.gov (NCT01667471). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.